动脉内持续尼莫地平输注治疗动脉瘤性蛛网膜下腔出血后严重难治性脑血管痉挛的副作用
该回顾性研究纳入2011年5月至2015年12月间接受至少5天持续动脉内尼莫地平输注(CIAN)治疗的28例急性非创伤性蛛网膜下腔出血后严重难治性脑血管痉挛患者,平均治疗时长10.5±4.5天。6个月时17例(60.7%)达到GOS 4-5分良好预后。CIAN期间及结束后第一天去甲肾上腺素支持的升压需求显著高于治疗前,2例发生心脏骤停需短时复苏,4例发生急性肾损伤(其中1例需持续低效每日透析),23例(82.1%)需升级抗感染治疗或启用抗生素,22例(78.6%)发生便秘,10例(35.7%)至少连续7天排便不足。与治疗前相比,CIAN全程颅内压显著升高。作者认为神经重症团队需认识这些副作用,避免CIAN对脑血管痉挛的获益被相关并发症抵消。
要点
- CIAN治疗期间及结束后第一天去甲肾上腺素支持的升压需求显著高于治疗前,2例发生心脏骤停需短时复苏。
- 23例(82.1%)在CIAN期间需升级抗感染治疗或启用抗生素,伴C反应蛋白和白细胞计数显著升高。
- 22例(78.6%)发生便秘,10例(35.7%)至少连续7天排便不足。
- CIAN全程颅内压较治疗前显著升高;4例发生急性肾损伤,其中1例需持续低效每日透析。
- 28例患者平均CIAN治疗10.5±4.5天,6个月后17例(60.7%)达到GOS 4-5分良好预后。
适用人群与场景
- 急性非创伤性蛛网膜下腔出血后严重难治性脑血管痉挛患者,接受至少5天持续动脉内尼莫地平输注(CIAN)治疗。
- 数据提取窗口为CIAN开始前2天至终止后5天。
处置流程与药物剂量
- 持续动脉内尼莫地平输注(CIAN)作为严重难治性脑血管痉挛的挽救治疗选择,本研究中28例患者平均治疗时长10.5±4.5天。
- CIAN期间需监测去甲肾上腺素支持的升压需求、通气参数与肺气体交换、肾功能、肝功能、胃肠道完整性及感染并发症。
- CIAN期间记录每日平均颅内压(ICP)值及与CIAN相关的颅内问题。
红旗征与不能漏的情况
- CIAN期间发生心脏骤停需短时复苏(原文报告2例)。
- CIAN期间需升级既往抗感染治疗或启用抗生素,伴C反应蛋白和白细胞计数显著升高(23例,82.1%)。
- CIAN全程颅内压较治疗前显著升高。
- 发生急性肾损伤(4例),其中1例需持续低效每日透析。
研究设计与关键结果
- 回顾性研究,纳入2011年5月至2015年12月间接受至少5天CIAN治疗的28例患者,平均治疗时长10.5±4.5天。
- 6个月后17例(60.7%)达到GOS 4-5分良好预后。
- 肺气体交换障碍仅发生于CIAN治疗最初阶段。
- CIAN期间所有天数及结束后第一天去甲肾上腺素升压需求显著高于治疗前。
- 2例在CIAN期间因心脏骤停需短时复苏;4例发生急性肾损伤,其中1例需持续低效每日透析。
- 23例(82.1%)需升级抗感染治疗或启用抗生素,伴C反应蛋白和白细胞计数显著升高。
- 22例(78.6%)发生便秘,10例(35.7%)至少连续7天排便不足;CIAN全程ICP较治疗前显著升高。
证据类型、等级与局限
- 回顾性研究,数据从患者数据管理系统提取。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为神经重症团队必须认识CIAN相关的血流动力学恶化、心脏问题、感染并发症增加、胃肠道动力下降及颅内压升高等副作用,以避免CIAN对脑血管痉挛的获益被这些并发症抵消。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Long-term continuous intra-arterial nimodipine infusion (CIAN) is a rescue therapy option in cases of severe refractory cerebral vasospasm (CV) following acute non-traumatic subarachnoid hemorrhage (SAH). However, CIAN therapy can be associated with relevant side effects. Available studies focus on intracerebral complications, whereas extracerebral side effects are rarely examined. Aim of the present study was to generate descriptive data on the clinical course during CIAN therapy and expectable extracerebral side effects.
METHODS: All patients treated with CIAN therapy for at least 5 days between May 2011 and December 2015 were included. We retrospectively extracted data from the patient data management system regarding the period between 2 days before the beginning and 5 days after the termination of CIAN therapy to analyze the course of ventilation parameters and pulmonary gas exchange, hemodynamic support, renal and liver function, integrity of the gastrointestinal tract, and the occurrence of infectious complications. In addition, we recorded the mean daily values of intracranial pressure (ICP) and intracerebral problems associated with CIAN therapy.
RESULTS: Data from 28 patients meeting inclusion criteria were analyzed. The mean duration of long-term CIAN therapy was 10.5 ± 4.5 days. Seventeen patients (60.7%) reached a good outcome level (Glasgow Outcome Scale [GOS] 4-5) 6 months after SAH. An impairment of the pulmonary gas exchange occurred only at the very beginning of CIAN therapy. The required vasopressor support with norepinephrine was significantly higher on all days during and the first day after CIAN therapy compared to the situation before starting CIAN therapy. Two patients required short-time resuscitation due to cardiac arrest during CIAN therapy. Acute kidney injury was observed in four patients, and one of them required renal replacement therapy with sustained low-efficiency daily dialysis. During CIAN therapy, 23 patients (82.1%) needed the escalation of a previous antiinfective therapy or the onset of antibiotics which was in line with a significant increase of C-reactive protein and white blood cell count. Obstipation was observed in 22 patients (78.6%). Ten patients (35.7%) even showed insufficient defecation on at least seven consecutive days. Compared to the situation before, ICP was significantly higher during the whole period of CIAN therapy.
CONCLUSIONS: Long-term CIAN therapy is associated with diverse side effects. The leading problems are an impairment of the hemodynamic situation and cardiac problems, an increase in infectious complications, a worsening of the motility of the gastrointestinal tract, and rising ICP values. Teams on neurointensive care units must be aware of these side effects to avoid that the beneficial effects of CIAN therapy on CV reported elsewhere are foiled by the problems this technique can be associated with.
参考来源
- Kieninger M, Flessa J, Lindenberg N, et al. Side Effects of Long-Term Continuous Intra-arterial Nimodipine Infusion in Patients with Severe Refractory Cerebral Vasospasm after Subarachnoid Hemorrhage. Neurocrit Care. 2018. PMID: 28685393. doi:10.1007/s12028-017-0428-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。